Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 164Breast Neoplasms 111Colorectal Neoplasms 77Neoplasms 65Lung Neoplasms 61Pancreatic Neoplasms 56Stomach Neoplasms 52Neoplasm Metastasis 51Ovarian Neoplasms 45Rectal Neoplasms 43Esophageal Squamous Cell Carcinoma 38Esophageal Neoplasms 38Head and Neck Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Leukemia, Myeloid, Acute 32Recurrence 26Triple Negative Breast Neoplasms 25Small Cell Lung Carcinoma 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Glioblastoma 23Colonic Neoplasms 23Uterine Cervical Neoplasms 22Nasopharyngeal Carcinoma 22Lymphoma 21Lymphoma, Non-Hodgkin 20Fallopian Tube Neoplasms 20Prostatic Neoplasms 17Melanoma 17Sarcoma 16Leukemia 16

Interventions

tanespimycin 2pembrolizumab 2parsaclisib 2cemiplimab 2Midazolam 2MLN 8237 2Injections 2Capecitabine 2zanidatamab 1tislelizumab 1spartalizumab 1sitravatinib 1repaglinide 1pemigatinib 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1drospirenone 1cabiralizumab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1MLN8054 1Ipilimumab 1HMPL-013 1Gemcitabine 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignancies × Drug Therapy × Clear all
NCT06468098 2024-07-18

A Study of IBI363 in Subjects With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
556 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡